Showing results (221-230 of 247) with videos related to
Sort By:
Pageof 25
JAMA Cardiology|November 3, 2022
Dapagliflozin and Kidney Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the DELIVER Randomized Clinical TrialFinnian R Mc Causland, Brian L Claggett, Muthiah Vaduganathan, et al.Circulation|June 6, 2024
Effect of Sacubitril/Valsartan on Cognitive Function in Patients With Heart Failure With Preserved Ejection Fraction: A Prespecified Analysis of PARAGON-HFPooja Dewan, Li Shen, João Pedro Ferreira, et al.Cardiovascular Diabetology|July 31, 2025
Efficacy and safety of dapagliflozin in patients hospitalized with COVID-19 with and without type 2 diabetes: a prespecified analysis of the DARE-19 randomized trialMohammad Abdel Jawad, Remo H M Furtado, Russell Esterline, et al.Journal of the American College of Cardiology|August 30, 2022
Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection FractionJonathan W Cunningham, Muthiah Vaduganathan, Brian L Claggett, et al.JACC. Heart Failure|July 15, 2019
Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF TrialAlvin Chandra, Muthiah Vaduganathan, Eldrin F Lewis, et al.Journal of the American College of Cardiology|August 30, 2022
Atrial Fibrillation and Dapagliflozin Efficacy in Patients With Preserved or Mildly Reduced Ejection FractionJawad H Butt, Toru Kondo, Pardeep S Jhund, et al.Circulation|October 21, 2024
Clinical Correlates and Prognostic Impact of Cognitive Dysfunction in Patients With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HFLi Shen, Pooja Dewan, João Pedro Ferreira, et al.Journal of the American College of Cardiology|September 1, 2022
Sacubitril/Valsartan and Frailty in Patients With Heart Failure and Preserved Ejection FractionJawad H Butt, Pooja Dewan, Pardeep S Jhund, et al.JAMA Cardiology|November 12, 2023
Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical TrialFinnian R Mc Causland, Brian L Claggett, Muthiah Vaduganathan, et al.European Heart Journal|August 27, 2022
Dapagliflozin for heart failure according to body mass index: the DELIVER trialCarly Adamson, Toru Kondo, Pardeep S Jhund, et al.Pageof 25